Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in RXRX.

← Back to Free Index

RXRX

Analysis as of: 2026-11-07

Recursion Pharmaceuticals, Inc.

Clinical-stage biotechnology company using its Recursion OS, automated labs, and compute stack to discover and develop small-molecule medicines and partnered drug programs.

ai automation biotech healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical proof will decide the rerating

The upside no longer needs a software-style fantasy. One approval-shaped internal asset plus repeated partner validation could justify a real rerating, but the next leg still depends on FDA clarity and clinical translation.

Analysis

Thesis

Recursion can rerate from speculative AI-biotech to validated platform-and-pipeline company if REC-4881 secures a registrational path, REC-1245 adds a second owned proof point, and Sanofi or Roche milestone cadence shows the lab-data engine repeatedly creates monetizable medicines before cash runway becomes the story again.

Last Economy Alignment

Cheaper cognition helps because Recursion owns the lab-data loop and captures value through licensing, milestones, royalties, and drug rights rather than seat pricing. The score stops short of elite because regulators, biology, and partner validation still gate monetization.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.4x (from 5 most recent analyses)

Reasoning

This is a rerating setup, not a simple revenue comp. If one owned asset becomes approval-shaped and at least one more owned or partnered program proves repeatability, investors can underwrite a blended business with orphan-drug sales, milestone and royalty streams, and higher-value discovery capacity. That supports multi-bagger upside, but not a frontier-AI premium because clinical proof still decides value capture.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not AI commoditization; it is that biology, the FDA, and a few partners capture the value before Recursion proves it can. Runway looks adequate into 2029, but 2031 upside still depends on REC-4881 earning a pivotal path, REC-1245 adding a second owned proof point, and platform validation becoming repeatable rather than episodic.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

November 2, 2026 results strengthened the lead asset case: REC-4881 showed deeper durability, off-treatment persistence, and activity in larger polyps.
November 2, 2026 updates also sharpened the second owned proof point, with REC-1245 showing early activity and a selected expansion dose.
October 15, 2026 Sanofi exercised its first development-candidate option, and the November update extended runway into 2029, reducing near-term financing pressure.

Thesis update

Not a regime change. The latest data and Sanofi event improve confidence that the platform can create value, but the core thesis still runs through the same FDA-path and repeatability gates.

Forecast update

No major classification change. Better lead-asset evidence and lower financing stress modestly improve upside, but the same regulatory permissioning still caps how far the rerating can go today.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.54

They own the lab-data loop, compute stack, and some drug rights, so cheaper AI can help them discover molecules faster without obvious seat-price collapse. But they only keep the big value if regulators and clinical data prove the discoveries matter.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$7.32

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research